Aligos Therapeutics

102 articles with Aligos Therapeutics

• Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference

  3/29/2023

  Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that the company presented Phase 1 data for its thyroid receptor-beta (THR-ß) agonist candidate, ALG-055009, at the 15th Paris Hepatology Conference, taking place virtually March 27 – 29, 2023.

• Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results

  3/9/2023

  Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2022.

• Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023

  2/28/2023

  Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”) today announced that it will report the Company’s fourth quarter 2022 financial results on Thursday, March 9, 2023 after the close of the U.S. financial markets.

• Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver

  2/16/2023

  Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that the company is delivering several oral and poster presentations at the 32nd Conference of the Asian Pacific Association for the Study of the Liver (APASL), being held Feb 15 – 19 in Taipei, Taiwan at the Taipei International Convention Center.

• Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver

  2/14/2023

  Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that the company will deliver several oral and poster presentations at the 32nd Conference of the Asian Pacific Association for the Study of the Liver (APASL), being held Feb 15 – 19 in Taipei, Taiwan at the Taipei International Convention Center.

• Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference

  2/10/2023

  Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the virtual SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 5:00 p.m. ET.

• Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024

  2/8/2023

  Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced a portfolio reprioritization.

• Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009

  1/5/2023

  Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company remains on track to complete all Phase 2-enabling activities in 2023 for ALG-055009, its thyroid hormone receptor beta (THR-ß) drug candidate for nonalcoholic steatohepatitis (NASH).

• Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)Single and multiple ascending doses to be evaluated in CHB subjects throughout 2023

  12/14/2022

  Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported today that dosing with ALG-125755, a small interfering RNA (siRNA) targeting the production of hepatitis B surface antigen (HBsAg), was initiated in subjects with chronic hepatitis B (CHB) in Study ALG-125755-501 (NCT05561530).

• Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting

  12/8/2022

  Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company presented the progress to date on the development of an oral pan-coronavirus therapeutic at the 2022 Respi DART meeting that was held December 6 – 8, 2022, in Los Cabos, Mexico.

• Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results

  11/2/2022

  Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the third quarter, September 30, 2022.

• Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022

  10/21/2022

  Aligos Therapeutics, Inc. today announced seven upcoming poster presentations at The Liver Meeting® (November 4-8, 2022), hosted by the American Association for the Study of Liver Diseases (AASLD).

• Aligos Therapeutics to Announce Third Quarter Results November 2, 2022

  10/19/2022

  Aligos Therapeutics, Inc. (Nasdaq: ALGS, the “Company”) today announced that it will report the company’s third quarter 2022 financial results on Wednesday, November 2, 2022 after the close of the U.S. financial markets.

• Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference

  10/18/2022

  Aligos Therapeutics, Inc. today announced that the Company will make an oral presentation at the Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference being held October 17-20, 2022 in Boston, MA.

• Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755

  10/14/2022

  Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported today that dosing with ALG-125755, an siRNA targeting the production of hepatitis B surface antigen (HBsAg), was initiated in healthy volunteers in Study ALG-125755-501 (NCT05561530).

• 

  Novartis, Merck, Janssen and More Face Patent Legal Battles

  9/30/2022

  This week had a flurry of biopharma patent cases, from Novartis vs Gilenya, Merck vs Viatris, and Aligos vs Janssen, either filed or court decisions being made. 

• Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results

  8/4/2022

  Aligos Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported recent business progress and financial results for the second quarter June 30, 2022.

• Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022

  7/27/2022

  Aligos Therapeutics, Inc. announced that it will report the company’s second quarter 2022 financial results on Thursday, August 4, 2022 after the close of the U.S. financial markets.

• Aligos Therapeutics Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating Its Class II Capsid Assembly Modulator, ALG-000184

  7/25/2022

  Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported that enrollment in a 12-week dosing cohort of HBeAg-positive chronic hepatitis B (CHB) subjects was initiated in the ongoing Phase 1b study ALG-000184-201 (NCT04536337).

• Aligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for CAM Drug Candidate ALG-000184

  6/22/2022

  Aligos Therapeutics, Inc. today announced that the company is presenting two posters showcasing preliminary Phase 1 data from its capsid assembly modulator (CAM) program in CHB.